

Amendments to the Claims

Please cancel Claims 3, 4, and 27-28. Note that Claims 15-21, and 24-26 were previously canceled. Please amend Claims 1, 2, 7, 9, 11, 13, 22, and 23. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently amended) A method of treating a vascular disorder in an individual, wherein the method comprises:
 - a. selecting an individual having an elevated G-coupled Protease Activating Receptor (PAR)-1 level, an elevated PAR-4 level, or both; and
 - b. administering an ~~[[effective]]~~ amount of a statin to the individual, wherein the statin is administered in an amount between 5 mg and 250 mg;wherein the PAR-1 level, the PAR-4 level or both are reduced, as compared to the level prior to step b), to thereby treat the vascular disorder.
2. (Currently amended) The method of Claim 1, further comprising selecting an individual who has a Total-Cholesterol (Total-C) of less than 200 mg/dL or Low Density Lipoprotein Cholesterol (LDL-C) level ~~[[in a normal range]]~~ of less than 130 mg/dL.
3. Canceled.
4. Canceled.
5. (Previously presented) The method of Claim 1, wherein the vascular disorder is selected from the group consisting of myocardial infarction, angina, stroke, pulmonary embolism, transient ischemic attack, deep vein thrombosis, thrombotic re-occlusion subsequent to a coronary intervention procedure, heart surgery or vascular surgery, peripheral vascular

thrombosis, Syndrome X, heart failure and a disorder in which a narrowing of at least one coronary artery occurs.

6. (Previously presented) The method of Claim 1, wherein the statin is selected from the group consisting of atorvastatin, an atorvastatin metabolite, pravastatin, a pravastatin metabolite, fluvastatin, a fluvastatin metabolite, cerivastatin, a cerivastatin metabolite, lovastatin, a lovastatin metabolite, simvastatin, a simvastatin metabolite, rosuvastatin, rosuvastatin metabolite, pitavastatin and a pitavastatin metabolite.
7. (Currently amended) The method of claim 6, wherein the statin is administered orally in ~~an amount between about 5 mg and about 250 mg per day.~~
8. (Previously presented) The method of Claim 1, wherein PAR-1 or PAR-4 are found on platelets.
9. (Currently amended) A method for treating a vascular disorder in an individual, wherein the method comprises:
 - a. assessing a level of PAR-1, PAR-4 or both in the individual, and comparing said levels to a control, wherein an elevated level of PAR-1, PAR-4 or both is determined; and
 - b. administering an ~~[[effective]]~~ amount of a statin to the individual, wherein the statin is administered in an amount between 5 mg and 250 mg;
wherein the elevated level of PAR-1, the PAR-4, or both are reduced to thereby treat the vascular disorder.
10. (Previously presented) The method of Claim 9, further comprising reducing levels of PAR-1, PAR-2 or both by at least 10%, as compared to the elevated levels of step a).

11. (Currently amended) The method of Claim 10, further comprising selecting an individual who has a Total-C of less than 200 mg/dL or LDL-C level [[in a normal range]] of less than 130 mg/dL.
12. (Previously presented) The method of Claim 9, wherein the vascular disorder is selected from the group consisting of myocardial infarction, angina, stroke, pulmonary embolism, transient ischemic attack, deep vein thrombosis, thrombotic re-occlusion subsequent to a coronary intervention procedure, heart surgery or vascular surgery, peripheral vascular thrombosis, Syndrome X, heart failure and a disorder in which a narrowing of at least one coronary artery occurs.
13. (Currently amended) The method of Claim 9, further comprising administering a vascular treating compound that includes aspirin, heparin, an ADP inhibitor, thienopyridine, ticlopidine hydrochloride, clopidogrel bisulfate, or a GPIIb/IIIa inhibitor.
14. (Previously presented) The method of Claim 9, wherein the statin is selected from the group consisting of atorvastatin, an atorvastatin metabolite, pravastatin, a pravastatin metabolite, fluvastatin, a fluvastatin metabolite, cerivastatin, a cerivastatin metabolite, lovastatin, a lovastatin metabolite, simvastatin, a simvastatin metabolite, rosuvastatin, rosuvastatin metabolite, pitavastatin and a pitavastatin metabolite.
15. Canceled.
16. Canceled.
17. Canceled.
18. Canceled.
19. Canceled.
20. Canceled.
21. Canceled.
22. (Currently amended) A method of [[preventing]] reducing one or more symptoms of a vascular disorder in an individual, wherein the method comprises:

- a. selecting an individual at risk for the vascular disorder, wherein the individual has an elevated PAR-1 level, an elevated PAR-4 level, or both; and
 - b. administering an ~~[[effective]]~~ amount of a statin to the individual, wherein the statin is administered in an amount between 5 mg and 250 mg;
- wherein the PAR-1 level, the PAR-4 level or both are reduced, as compared to the level prior to step b), to thereby ~~[[prevent]]~~ reduce one or more symptoms of the vascular disorder.

23. (Currently amended) A method of ~~[[preventing]]~~ reducing one or more symptoms of a vascular disorder in an individual, wherein the method comprises:
- a. assessing a level of PAR-1, PAR-4 or both in the individual, and comparing said levels to a control, wherein an elevated level of PAR-1, PAR-4 or both is determined; and
 - b. administering an ~~[[effective]]~~ amount of a statin to the individual, wherein the statin is administered in an amount between 5 mg and 250 mg;
- wherein the elevated level of PAR-1, the PAR-4, or both are reduced to thereby ~~[[preventing]]~~ reduce one or more symptoms of the vascular disorder.
24. Canceled.
25. Canceled.
26. Canceled.
27. Canceled.
28. Canceled.